Negative Regulation of c-Abl by PtdIns(4,5)P 2 A previous study [6] demonstrated that the kinase activity of the membrane-associated c-Abl pool was transiently increased upon treatment of fibroblasts with certain growth factors, including platelet-derived growth factor (PDGF), and that Abl was required for PDGFinduced membrane ruffling. Activation of Abl by PDGF was greatly impaired in fibroblasts deficient in c-Src, Yes, and Fyn or in wild-type fibroblasts expressing a chimeric PDGF receptor lacking the Src-binding sites at tyrosines 579 and 581. Since the catalytic activity of purified c-Abl is stimulated by tyrosine phosphorylation [7] , these observations suggested that Src kinases are directly activated by the PDGF receptor, and then phosphorylate and activate c-Abl in a secondary reaction. In a follow-up study in Nature Cell Biology, Ann Marie Pendergast and co-workers [3] have now shown that PDGF receptor signaling also overcomes negative regulation of c-Abl mediated by membrane phospholipids.
The key observation was that the binding site for phospholipase C-γ γ1 (PLC-γ γ1) at Tyr1021 on the PDGF receptor is required in addition to the Src-binding sites for robust PDGF-induced activation of c-Abl (Figure 1) . Activation of c-Abl by PDGF is impaired by pre-treatment of cells with a PLC-γ γ inhibitor, diminished in fibroblasts lacking PLC-γ γ1, and restored by expression of wild-type but not phospholipase-inactive PLC-γ γ1. This finding suggests that either the substrate of PLC-γ γ, phosphatdylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ), inhibits Abl or the products of the reaction, inositol-3,4,5-triphosphate (InsP 3 ) and diacylglycerol, stimulate Abl. Pendergast and colleagues [3] found that InsP 3 does not affect Abl kinase activity in vitro, but addition of liposomes containing PtdIns(4,5)P 2 inhibits c-Abl and this is significantly enhanced by pharmacological levels of calcium (400-800 µ µM). [8] . c-Abl is dysregulated by mutations in the SH3 domain that interfere with ligand binding [9] , and a seminal 1998 paper from the laboratory of Giulio Superti-Furga demonstrated that mutation of the homologue of Pro250 in c-Abl also activates Abl [10] , suggesting that Abl shares this part of the regulatory mechanism with Src. Point mutations in the connector region between SH3 and SH2 also dysregulate both Src and Abl [11, 12] , implying that dynamic coupling between the two domains is necessary for proper regulation of both kinases. However, Abl has no detectable tyrosine phosphorylation when expressed at physiological levels [9] and is not dysregulated by deletion of the entire carboxyl terminus or by point mutations in the SH2 domain that block phosphotyrosine binding [13] . Thus, it has been an enigma how an inhibited state of Abl could be maintained when Abl lacks the SH2-Tyr527 interaction that is essential for regulation of Src.
In a pair of recent papers in Cell, the laboratories of Superti-Furga and John Kuriyan have collaborated to give us the first structural glimpse of Abl in the inactive state. An amino-terminal fragment of Abl that lacks the first exon and ends with the catalytic domain would crystallize only when myristate fatty acid was added in trans [5] . The resulting structure reveals the myristate group bound in a deep hydrophobic pocket within the carboxy-terminal lobe (C-lobe) of the catalytic domain, inducing a kink in a carboxy-terminal α αI-helix that permits close docking of the SH2 domain to the back face of the C-lobe via a series of hydrogen bonds. The overall structure bears a striking similarity to inactive Src, with the SH3 domain engaged with the Pro250 homologue in the SH2-CD linker. The accompanying paper [4] provides biochemical and genetic support for the structure by demonstrating that Abl sequences amino-terminal to the SH3 domain (the amino-terminal 'cap') and the myristoyl group are required for proper regulation of type Ib Abl kinase activity upon overexpression in vivo. The catalytic activity of Abl is also increased by mutations at the predicted SH2-kinase domain interface and by phosphotyrosine ligands that may disrupt this interaction.
Multilevel Regulation of c-Abl
These recent studies add to an emerging picture of c-Abl as a multifunctional protein localized to at least three different cellular compartments and whose catalytic activity is regulated on several levels by different mechanisms (Figure 2 ). In the membrane-associated pool of Abl, the myristoyl group is presumably inserted in the lipid bilayer and unavailable for binding to the C-lobe. In this context, inhibition of Abl may be mediated by PtdIns(4,5)P 2 , possibly acting through an accessory protein. One could speculate that PtdIns(4,5)P 2 , which binds directly to the catalytic domain of Abl [3] , might cause a conformational change in the C-lobe similar to that induced by myristate. In contrast, the cytoplasmic and cytoskeletal pools of Abl may assume an autoinhibited state suggested by the crystal structure [5] , with the myristoyl group buried in the C-lobe. This inactive conformation could be disrupted by several routes, including autoor transphosphorylation at regulatory tyrosines in the activation loop of the catalytic domain and the SH2-CD linker [7] , or displacement of the SH2 or SH3 domains, or the myristoyl group [4] .
However, there are several aspects of Abl biology that must still be explained. c-Abl gains significant catalytic activity when overexpressed [14] or upon purification [7] and its enzymatic activity in solution is unaffected by loss of the myristoyl group [15] . Furthermore, when expressed at physiological levels, type Ia c-Abl is regulated despite the lack of a myristoyl group, as is a c-Abl Ib mutant lacking the myristoylation site and first 45 residues of the cap [16] . These observations suggest that Abl may also be regulated in vivo by cellular factors. In the studies of Kuriyan and colleagues [4] 
